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INTRODUCTION 
 
Stroke is now considered as an important health problem for all 
individuals and society. After Acute myocardial infarction and malignancy, 
Ischemic stroke is the third leading cause of death and is also as leading cause 
of hospitalization causing disability.  So we have to identify the stroke at an 
earlier date which help the treating physicians to plan treatment, make 
interventions and to provide significant benefit to the people and community 
and to save the patient . The conventional risk factors namely blood pressure 
(BP), smoking, diabetes, dyslipidemia, alcohol predict the happening of stroke, 
but still they are not completely reliable, therefore there is a continuous debate 
and search for prediction of occurrence of stroke  and reliability of  prognostic 
markers in stroke have gained interest in recent years. 
 
      When an individual is exposed to any insult in terms of infection and 
injury, there is a production of proteins called Acute Phase Proteins. This 
Acute phase protein participates in all inflammatory process and plays a major 
role in both acute and chronic inflammatory states. The Acute phase reactants 
are fibrinogen, ferritin, haptoglobin, highly sensitive C – reactive protein, 
Complements (C3), Complements (C4), Tumour necrosis factor. Among these 
various proteins, Highly sensitive C-reactive protein have gained wide 
recognition in monitoring different diseased states and it leads to the 
development of reliable and fast assay measuring their plasma levels. 
In recent years, inflammatory process plays an important role in 
pathophysiology of stroke. The initiator of extrinsic pathway of coagulation is 
Tissue factor. This tissue factor got expressed when mainly monocytes are 
stimulated by C-reactive protein and initiates vascular thrombosis. hsCRP, a 
marker of Atherosclerosis and also a peripheral marker of inflammation found 
to be valuable in sorting out of possible risk factors of subsequent 
cerebrovascular and cardiovascular (CV) events, Peripheral Arterial Diseases 
or death. This important fact was also supported by abundant laboratory and 
experimental evidence demonstrating that atherosclerosis refers to chronic 
inflammatory process. 
         High plasma levels of CRP are not specific to disease, but it is sensitive 
marker and is produced in response to tissue injury, infectious agents and 
inflammation. hsCRP predicts the first cardiovascular event in general 
populations . hsCRP is the only inflammatory marker which independently 
predicts the future risk of stroke when measured prior to onset of clinical 
disease. 
 hsCRP is now widely determined as valuable and good prognostic 
indicator in stroke because of the following reasons: 
 Severity of stroke correlates positively with hsCRP concentration and 
these levels also denotes the degree of inflammation secondary to 
infarction of the brain. 
 Reflects the underlying Atherosclerotic Disease. 
 
         
 
 
 
 
 
 
                             
                                       
 
 
                
AIMS & OBJECTIVES 
 
1)  To evaluate the prognostic significance of hsCRP with severity of 
      stroke in correlation with stroke scales (NIHSS and MRS ). 
 2) To evaluate the relationship between hsCRP and various risk factors 
      for stroke, with territory of infarct and other findings in CT film. 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
REVIEW OF LITERATURE 
 
 
HISTORICAL REVIEW 
 
          Stroke was first recognized by Hippocrates, the Father of Medicine 
about 400 BC. During that period, Stroke was described as Apoplexy which 
denotes “Struck down by Violence” in Greek .1 
                 In 1658, Johann Jacob Wepfer states that stroke occurs 
predominantly due to disruption of blood flow to the brain. In 1847, Rudolf 
Karl Virchow, who is a German pathologist, identified atherosclerosis and 
clotting mechanism is the definitive cause of ischemic stroke. 
2 
                
Hounsefield introduced the concept of Computed Tomography in mid-
1960s, which helps in the clear distinction between brain ischemia and 
haemorrhage. Then Magnetic Resonance imaging was introduced in mid 
1980s which remains superior to CT scans and it helps to identify posterior 
fossa lesions.
1
 In 1950, Craven identified aspirin as an anticoagulant property 
and it was used for stroke only by mid 1970s . Thrombolytic therapy for 
ischemic stroke was introduced in early 1960s, but only in 1995 it was 
approved by United States Food and Drug Administration for thrombolytic 
therapy for ischemic strokes.
1 
      Stroke or cerebrovascular accident is defined by abrupt onset of a 
 Neurologic deficit that is due to focal vascular cause. 
 
EPIDEMIOLOGY 
       In United states, stroke now ranks as third common cause of death, after 
myocardial infarction and cancer, it also considered as leading cause of 
disability.
6
 Among 7,00,000 cases of reported strokes (includes 6,00,000  
cases of Ischemic stroke and 1,00,000 cases of haemorrrhages, intra cerebral, 
sub-arachnoid haemorrhages), about 20% of cases were dying within one year 
of incidence of stroke. If such incidence continues, this number will reach 1 
million cases  per year by 2050.
7
 Stroke accounts for 5.7 million deaths and 16 
million first ever cases worldwide in the year  2005 .
8
 
      In India, about 1 million cases were reported in the year 2003, for every 
one lakhs population in the people of age group more than 20 years and it also 
contributes 1.2 % of the total deaths.
9
 In the study conducted by Banerjee and 
Das, reports age adjusted prevalence rate ranges between 250 -350 per one 
lakhs Population.
12
 As per Indian Council Medical Research (ICMR) reports, 
that Stroke accounts for 41% mortality and 72% morbidity (Disability 
Adjusted Life Years) among the non communicable diseases.
10 
Stroke and 
diabetes together brings the estimated national economic loss of approximately 
9 billion dollars in India between 2006 to 2015. Based on the incidence of 
stroke study reported from Eastern India, the adjusted annual incidence was 
124 in rural areas,
 13
 and 145 in urban areas .
14
  
 
CLASSIFICATION OF STROKE 
5
 
 
Stroke can be classified in different ways. 
Based on Clinical features: 
22 
1. Completed stroke 
2. Stroke in Evolution  
3. Transient Ischemic Effects 
4. Reversible Ischemic Neurological Deficit 
Based on Anatomical Location: 
1. By vascular supply 
a. Carotid artery 
b. Vertebrobasilar artery 
2. By location 
a. Supra-tentorial which includes lobar and Capsulo-gangilionic 
b. Infra-tentorial which includes brainstem and cerebellum 
3. Based on Etiology 
By pathology 
a. Ischemic 
b. Haemorrhagic  
 
ETIOLOGY
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Common causes 
 
Uncommon causes 
 
Thrombosis  
                                              
Large vessel thrombosis 
      Lacunar stroke (small vessel) 
      Dehydration 
 
 
Embolic Occlusion 
   Cardio –embolic 
       Myocardial infarction 
       Mural thrombus 
       Atrial fibrillation 
 
   Dilated cardiomyopathy 
 
Cardiogenic   
   Marantic Endocarditis 
   Libman sacks Endocarditis 
   Intracardiac mass 
   Mitral valve calcification 
   Atrial myxoma 
 
Vasculitis 
    Primary CNS vasculitis 
    Systemic Vasculitis –  
        Wegener‟s Granulomatosis,   
         Polyarteritis  Nodasa,  
        Takayasu arteritis , 
        Giant  Cell arteritis ,   
    Valvular lesions –mechanical  
    valves, Mitral stenosis,  
    bacterial  endocarditis 
 
    Atrial sepal aneurysm 
 
    Spontaneous ECHO contrast 
 
    Paradoxical embolus- Patent  
 
    Foramen ovale ,   
    Atrial septal defect 
 
Artery to Artery 
 
    Aortic arch 
 
   Carotid artery  bifurcation 
 
   Arterial dissection 
        Meningitis   
       (Tuberculosis, syphilis,   
bacterial, fungal, Bacterial, Zoster) 
Hypercoagulable disorders 
   Antiphospholipid Antibody  
   Syndrome, Protein C deficiency,                                                             
Protein S deficiency, Antithrombi 
III deficiency , Prothrombin  
    G20210 mutation ,  
    Systemic lupus erythematosis, 
    Thrombotic thrombocytopenic  
    Purpura , Disseminated    
    Intravascular coagulation,                                                           
systemic  Malignancy ,  
    thalessemia ,  
    Inflamamtory bowel disease,  
    Oral 
    Contraceptive pills,  
    Homocysteinmia. 
Dysproteinemias 
Eclampsia,Moyamoya disease 
Drugs –cocaine, Amphetamine . 
Subarachnoid haemorrhage 
vasospasm  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RISK FACTORS
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            IRREVERSIBLE 
 
          MODIFIABLE 
Age 
 
Sex ( male > female, not applicable in 
 
 very young and very old ) 
 
Hereditary 
 
Race (Afro-carribean population 
>Asian  
 
population> European population) 
  
 
Raised Blood Sugar 
 
Hypercholesterolemia 
 
Elevated Blood pressure 
 
Smoking 
 
Sickle cell Anaemia 
 
Polycythemia 
 
Excessive consumption of 
alcohol 
 
Cardiac Causes 
1. Atrial fibrillation 
  
2. Infective endocarditis 
 
3. Heart ailure 
 
4. Hypertrophy of left 
ventricle 
 
5. Recent myocardial 
infarction 
 
6. Congenital heart 
disease and 
malformations 
 7. Mitral stenosis 
 
 
Oral contraceptive pills 
 
Physical inactivity 
 
Head and neck injuries 
 
AGE: 
 People of any age group can be affected by stroke. Incidence of stroke 
increases with increasing age. 
SEX: 
 Men are more commonly affected with stroke than women.  Young 
stroke is more common in young female using oral contraceptive pills and in 
pregnant individuals. 
RACE: 
 The occurrence of ischemic stroke is more common among the Asians 
and Blacks. 
HYPERTENSION: 
 The risk of stroke is increased four to six times in hypertensive patients. 
Since hypertension promotes the atheroma formation in all sized vessels of 
brain, hypertension is considered as important risk factor for stroke. 
DIABETES: 
 Diabetic individuals are three times more prone for than individuals who 
are not diabetic. Diabetes also promotes the atheroma formation, thereby 
increasing the rate of occlusion of intracranial arteries. 
SMOKING: 
 Smoking increases the stroke risk by two times. Smoking causes 
vasoconstriction, increases fibrinogen concentration, causes polycythemia, 
reduces aggregation of platelets, all these contributes stroke occurrence. 
ALCOHOL: 
 High Alcohol Consumption increases the risk of stroke . 
Syndromes of cerebral infarction.
16 
 
Carotid Artery occlusion 
1. Amaroux fugax which is also known as transient monocular    
blindness.  
 2. Speech disorder 
 3. UMN type of facial palsy 
 4. Loss of sensation in one half of the body(cortical type of sensory     
             loss) 
 5. Weakness of one half of the body 
6. Hemianopia  
Anterior cerebral artery Infarct
23
 
 When anterior cerebral artery is blocked distal to the anterior communicating 
Artery, patient will have following features 
 Contalateral hemiplegia and hemisensory loss with predominant lower 
limb involvement 
 No facial involvement 
 Urinary incontinence 
 Emotional disturbances 
 Presence of released reflexes  
When anterior cerebral artery is blocked proximal to the anterior 
communicating Artery, patient will have 
 Complete hemiplegia which denotes hemiplegia and facial involvement 
on the opposite side of the body with or without aphasia. 
Middle cerebral artery infarcts 
Occlusion of Stem of Middle cerebral artery causes 
a. global aphasia 
b. contralateral hemiplegia 
c. contralateral hemianaesthesia 
d. contralateral hemianopia 
e. apractagnosia, dysarthria, contralateral neglect in non dominant 
hemisphere involvement. 
Occlusion of proximal superior division of MCA will cause motor weakness, 
sensory disturbances  and motor aphasia. 
Occlusion of Inferior division of MCA will cause 
 Wernicke‟s aphasia without weakness 
 Sometimes quadrantopsia 
 In non dominant hemisphere, hemineglect and spatial agnosia  can occur 
without weakness. 
Posterior cerebral artery syndrome
22
 
Signs and symptoms Structures involved 
Homonymous hemianopia Calcarine cortex 
Cortical blindness, denial of 
blindness, apraxia of ocular 
movements 
Bilateral occipital lobe involvement 
Dyslexia without agraphia Dominant calcarine lesions 
Memory defect Dominant temporal lobe 
prosopagnosia Non dominant calcarine and lingular 
gyri 
Simultagnosia Bilateral visual cortex 
 Vertebral artery Occlusion 
Wallenberg's syndrome occurs due to the Posterior inferior cerebellar 
artery occlusion (PICA), vertebral, or superior, middle or inferior lateral 
medullary arteries. This syndrome is characterized by contralateral impaired 
pain and temperature sensation (spinothalamic tract involvement) and the 
same side Numbness over half of the face, ataxia, Horner‟s syndrome, 
dysphagia, vertigo, hiccups and loss of taste sensation.  
Basilar artery syndrome 
Complete basilar artery syndrome causing coma due to ischemia of high 
midbrain reticular activating system, quadriparesis along with facial 
involvement, ophthalmoplegia and loss of corneal and pupillary reflexes. In 
contrast, partial basilar artery syndromes will usually results in locked-in 
syndrome, top-of-the-basilar syndrome.  
In locked in syndrome, the pathology is infarction of base of Pons 
resulting in quadriparesis along with loss of facial expressions, loss of 
horizontal eye movements. Consciousness is retained due to sparing of 
reticular activating system, but vertical movement of eye is present.  
In top-of-the-basilar syndrome, the presenting clinical picture will be 
hemianopia or complete cortical blindness, amnesia vertical gaze palsies, and 
hallucinations. 
Single perforating artery Occlusion 
'Lacunar syndrome' occurs mainly due to the occlusion of one of many 
arterioles which arises perpendicularly from large parent artery to supply little 
areas in deep areas of brain and brain stem. Here, the affected individual will 
not have any features suggestive of aphasia, hemianopia, neglect and 
conjugate deviation of eyes.
4 
 
Clinical features
3
 
 
 
Structure involved 
 
 
Pure motor hemiparaesis 
 
 
Infarct in the posterior limb of 
Internal capsule, basis pontis 
 
Pure sensory stroke 
 
 
Ventral thalamus infarct 
 
Ataxic Hemiparaesis 
 
 
Ventral pons infarct 
 
Dysarthria and clumpsy hand 
syndrome 
 
Genu of internal capsule infarct 
  
 
PATHOPHYSIOLOGY OF ISCHEMIC STROKE
3
  
 
Ischemia occurs due to the acute occlusion of intra-cranial vessels 
resulting in reduction in blood flow to brain tissues. These amount of blood 
flow reduction depends on location of blood vessels, site of occlusion, 
adequacy of collateral blood vessels and blood pressure.
3 
 
  
Amount of blood flow\ gram 
brain tissues\ minute 
   
 Effect on brain tissues  due to 
decreased blood flow 
 
                         Zero 
 
                      Death 
 
                    < 16 -18 ml 
 
           Infarction (within 1 hour) 
 
                   < 20 ml 
 
           Ischemia(without infarction, 
if it is not prolonged for several 
hours or weeks ) 
 
  
 
ISCHEMIC PENUMBRA
 
 
ISCHEMIC PENUMBRA is a dense central core surrounded by a less 
dense zone of Ischemia but function can be reversed and restoring the blood 
perfusion prevents the death of brain tissues. The viability of neuronal cells in 
these is 3 hours, so blood flow should be restored by adopting various 
reperfusion techniques and or neuroprotective agents, hence this period is 
considered as “Therapeutic Window period”.5 This zone can be detected in the 
CT or MRI using Diffusion perfusion imaging.
3
  
PATHOGENESIS 
      Cerebral infarction occurs due to two different mechanisms namely 
necrotic and apoptotic mechanisms. In this necrotic mechanism, starvation of 
neurons causes mitochondrial dysfunction which causes energy failure which 
in turn leads on to neuronal depolarization. These causes increase in 
intracellular calcium ions and increased glutamate release from synaptic 
terminals, which leads on to neurotoxicity.
3 
Energy failure also causes lipolysis 
and release of free radicals , platelet activating factors, arachidonic acid and all 
these results in neuronal injury.
5
 In ischemic penumbra, apoptotic pathway 
operates causes neuronal  cellular death in days or weeks later . Fever and 
hyperglycemia (>200 mg/dL) causes detrimental effects in outcome of stroke 
and they further worsens ischemia and promotes cellular death.
3
 
       Among the ischemic stroke incidence, cardio-embolism constitutes 20%. 
In heart disease, thrombi attached to left heart wall, atrial, ventricular wall 
detach and enters systemic circulation, these thrombi lyses quickly and causes 
Transient Ischemic Attacks or stroke. These Emboli lodges frequently in 
Middle cerebral Artery or Posterior cerebral Artery but rarely in anterior 
cerebral artery.
3 
ATHEROSCLEROSIS 
     Atherosclerosis is one of the major causes of death and atherosclerosis of 
coronary arteries, intracranial and extra cranial vessels, peripheral arteries 
causes coronary artery disease, cerebrovascular accidents, intermittent 
claudication respectively.
3
 The characteristic feature of Atherosclerosis is 
Atheromas which is formed by thickening of tunica intima and accumulation 
of lipids. The atheromatous plaques consists of central core which is formed 
by cholesterol esters and cholesterol  and it is covered by a fibrofatty plaques 
and this forms a raised lesion in the tunica intimal layer.These atheromatous 
plaques will undergo changes such as calcification, ulceration or rupture of 
thrombus and exposes the underlying thrombogenic materials resulting in 
superadded thrombus formation.
17 
RISK FACTORS FOR ATHEROSCLEROSIS
17 
Non modifiable risk factors are Elderly age, male sex, genetic 
predisposition, whereas potentially modifiable risk factors are diabetes 
mellitus, hypertension, cigarette smoking, and hypercholesterolemia. And the 
less quantifiable risk factors are sedentary life style, central obesity, increased 
stress, hyperhomocysteinemia, increased alcohol consumption, estrogen 
deficiency in post menopausal women;etc.
17
 About 20% of ischemic stroke 
occurs due to carotid atherosclerosis and in carotid arteries; common carotid 
atery bifurcation and proximal internal carotid artery are the most common 
sites for atherosclerosis.
3 
IMAGING STUDIES  
CT SCANS 
CT scan helps in the clear differentiation between haemorrhages and infarct 
and it also helps to detect abscess, tumour mass lesions, extra parenchymal 
haemorrhages (extra dural and sub dural haemorrhages).
3 
Merits: 
1.  CT distinguishes infarct and haemorrhages and helps the treating Physician 
     to decide the line of management.          . 
2. CT scans are highly sensitive in detecting Subarachnoid Haemorhage. 
Demerits: 
1. When CT scans are taken in an acute set up, ct scans will not usually 
   detect the infarct in the first 24 to 48 hours. 
2. CT scans misses the small infarct on the cortical surface. 
3. Usually CT scans will not detect the posterior fossa lesions due to                                 
artifact (bone). 
INFARCT: CT scans shows infarct as a hypodense lesion.  When there is 
hypodense marking of particular vein, gray enhancement and post contrast 
enhancement of that particular vein in CT scans, such finding favors 
thrombosis of cortical veins of the brain. 
HAEMORRHAGE: Hyperdense lesions or areas in the film indicates 
haemorrhages. About 1cm or more in diameter haemorrhages will be detected 
in CT scans.  
 CT FINDING IN CEREBRAL INFARCTION
18
 
 
     
Timing of Infarct 
 
            CT Findings 
 
Hyperacute (<12 hours) 
Lentiform Nucleus obscuration 
Increased dense lesions (25 – 50 %) 
Normal (50%) 
Acute (12 to 24 hours) Effacement of sulcus, Insular ribbon sign–
loss of grey and white matter differentiation.                                 
 
Days 1 day to 7 days  
Transformation of infarct into haemorrhages, 
Enhancement of Gyrus, Mass effect, Low 
 density areas which is wedge shaped, 
involving white and grey matter. 
Weeks :1-8 Resolving of mass effects, persistence of 
contrast enhancement.  
Months to year
 
Encephalomalacia changes. Loss of Volume 
 
MRI SCANS
3
 
1. Posterior fossa infarction and cortical infarction can be easily identified 
in these scans and so it was considered superior and more sensitive than 
CT scans in such lesions. 
2. Early brain infarction can be easily determined by Diffusion weighted 
images and this imaging modality is more sensitive.      
3. Stenosis of intracranial vessels and extracranial internal carotid arteries 
stenosis were detected by MR Angiogram. 
COMPLICATIONS OF STROKE
15
 
1. Aspiration Pneumonia, Urinary tract infection 
2. Bed sores. 
3. Pulmonary embolism with Deep vein thrombosis. 
4. Contractures. 
5. Dehydration. 
6. Hypoxemia 
7. Hyperglcemia 
8. Frozen Shoulder and subluxation 
9. Constipation   
10. Dehydration, Hyponatremia and seizures.
[15] 
TREATMENT 
            The laboratory investigation and treatment of stoke should be done 
in proper order as soon as clinical diagnosis of stoke is made.  
Goal of treatment: prevention of brain injury or reversal of ischemic brain 
damage. 
General treatment strategies of Stroke treatment 
1. Risk factors for Stroke should be controlled, in order to prevent further 
cerebrovascular accidents. 
2. Prevent stroke complications. 
3. Specific pathology and patho-physiologies should be treated.[1] 
4. Airway  should be secured , breathing , circulation  should be 
maintained. 
5. Blood sugar should be maintained within normal limits.   
6. Emergency non contrast Computed tomography films should be taken, 
since it helps to distinguish between ischemia and haemorrhage. 
7. Points that favors  Hemorrhagic stroke at that the time of presentation 
were Initial Maximum deficit, altered or diminished level of 
consciousness and increased blood pressure   and the points that denotes 
Infarct were maximal at onset or remits after onset.
[3]
 
8. Promotion of recovery of stroke patients. 
9. Improve neurological function. 
TREATMENT CATEGORIZATION 
3 
1. Medical therapy 
2. I.V. thrombolysis 
3. Anti thrombotic treatment 
4. Endovascular techniques 
5. Neuroprotection 
6. Stroke rehabilitation 
Medical management 
Aim of therapy:  
To restore blood flow around ischemic penumbra. 
1. I.V. Mannitol: Cerebral edema usually peaks around 2nd to 3rd day and it 
will last for 10 days, so I.V. Mannitol should be given in order to reduce 
cerebral edema. If it is not treated, it will result in herniation of the brain 
and finally it leads to sudden cardio-respiratory arrest and in such cases 
Hemi-craniotomy, where part of the skull can be removed temporarily.  
2. Blood pressure monitoring and its reduction is necessary only when 
there is associated myocardial infarction, and the patient is planned for 
thrombolytic therapy (>185/110mmHg), Hypertensive emergencies. 
3. Deep vein thrombosis prophylaxis should be given, by adding 
Subcutaneous Heparin ( Unfractionated Heparin ) 
4. Heart rate reduction should be done with β1blocker Esmolol, which 
helps to restore maintain the mean arterial pressure to brain. 
5. Hyperthermia should be treated with cooling blankets. 
6. Blood sugar monitoring should be done since hyperglycemia results in 
poor outcome and it should be maintained around 110mgs/dL.
3
 
I.V. Thrombolysis 
Recombinant tissue plasminogen activator (rt-PA) is now used as a 
thrombolytic agent of choice. The incidence of intracranial haemorrhage is 
minimal with this drug. The time window period for administering rt-PA in 
patients with ischemic stroke is 3 hours but it can be extended up to a 
maximum of 6 hours. The recommended dose of rt-PA is 0.9 mg /kg and the 
maximum dose of this drug is 90 mg. 10% of the drug should be given as i.v. 
bolus and remainder as intravenous infusion over a period of one hour. 
Frequent monitoring of blood pressure while administering this drug as 
infusion through large peripheral vein and infusion should be stopped once 
patient developed signs of neurological deficit and cryoprecipitate should be 
administered in such case. Urinary catheterization should be avoided for 
another 2 hours.
3
 
Indications for thrombolysis 
1.  Clinical diagnosis of stroke should be made. 
2.  Patient should remain in the category of therapeutic window  
      period of 3 hours.    
3. There should not be any evidence of haemorrhage, edema, infarct  
     involving more than 1/3 of involved infarct territory, mass effect,  
     edema in CT scan. 
4.  Patient should be >18years. 
5.  Consent by patient attenders.
3
 
 
Contra indications for thrombolysis 
 1. BP >185/110 mmHg inspite of treatment.  
2. Patient having completed stroke in last 14 days or TIA 
symptomatalogy, and patient presenting with any upper and            
lower Gastrointestinal bleeding in previous 3 weeks, Recent  
    myocardial infarction, Comatosed or stupor. 
 3. Platelets < 1 lakhs / cu.mm ; PCV < 25% ;   
             Glucose <50 or >400 mgs /dL. 
4. Heparin should not be used in preceding 48hours and elevated  
    aPTT / INR . 
5. Proir stroke or head trauma in last 90 days or prior intracranial  
    haemorrhage. 
6. When patient consciousness is lost (in comatosed state) or 
    patient remaining in a stuporous condition. 
ANTITHROMBOTIC TREATMENT 
Platelet inhibition: Thrombaxane A2 is a prostaglandins, which is a platelet 
aggregator as well as vasoconstrictor. Aspirin acetylates the cyclooxygenase of 
platelets and completely inhibits the platelet plug formation .This platelet plug 
inhibition is irreversible. The anti-platelet activity of acetyl salicyclic acid will 
remain for atleast 8 days. Low dose aspirin should be given as once daily dose. 
It will inhibit only thromboxane A2 production and the inhibition of 
prostacyclins is spared. So generally recommended dose for stroke is 50-325 
mg/day.
3 
ANTICOAGULATION 
Anticoagulation should be advised for all patients with atrial fibrillation 
which is due to non valvular heart disease and cardiac disease. Cerebral 
embolism can be prevented by maintaining an INR of 2-3. This 
anticoagulation can be brought out effectively by Vitamin K antagonists.  
Indications for 3 month of anticoagulation 
1. Left ventricular dysfunction 
2. Atrial fibrillation 
3. Anterior Q –wave infarction 
4. Mural thrombus 
5. Congestive cardiac failure 
ENDOVASCULAR TECHNIQUES 
Endovascular techniques should be planned for all patients for whom 
thrombolysis failed and contra-indications for thrombolysis exist .These 
candidates were eligible for endovascular mechanical thrombectomy. And by 
this procedure, blood flow to the occluded vessels can be established within 8 
hours of stroke.
3
 
NEUROPROTECTION 
These neuroprotective drugs will block the neuro- excitatory amino acid 
pathways and it promotes the tolerance of brain to ischemic effects. Some of 
the drugs which gives neuroprotection are Calcium Channel Antagonists (ex. 
Nimodipine , flunarizine,darodipine), Non competitive N-methyl–D-aspartate 
receptor antagonists (ex. dextromethorpan, eliprodil), Phosphatidyl choline 
synthesis (eg. Citicoline).
1
 
STATINS 
Statins are the inhibitors of 3-hydroxy -3 methylglutaryl coenenzyme A 
reductase inhibitor. These drugs were effective in reducing the cholesterol 
levels particularly low density lipoproteins. And it was found very effective in 
reducing the incidence of Coronary artery disease and cerebrovascular 
accidents. These statins has the following properties: 
1. Normalizes the vascular endothelium 
2. Reducing inflammation 
3. Stabilizes the plaques mainly the central lipid core mass. 
4. Reduces the platelet-fibrin thrombi and decreased white clots deposition 
on the endothelial surfaces. 
5. Fibrous caps of atheromatous plaques get strengthened and stabilized. 
6. Thrombogenicity of the atheromatous plaques gets decreased.1 
STROKE REHABILITATION  
 Speech therapy  
 Occupational therapy 
 Physical therapy 
 Pharmacological therapy.3 
ACUTE PHASE REACTANTS 
       In 1941, Avery and Theodore J Abernethy coined the term Acute Phase 
Reactants and also denoted that acutely ill patient‟s serum contains CRP. 
       Acute phase reactants are the markers of inflammation and they are 
elevated in inflammation, infection and they tend to appear or rise in the blood 
whenever the immune system comes in contact with proteins. This elevation of 
acute phase reactants indicates inflammatory burden and it gets elevated in 
vascular events.
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 Some of the acute phase reactants are 
 α1 globulin 
 α2 globulin 
  α1anti trypsin 
 Fibrinogen 
 Fibrinonectin 
  Serum Amyloid A protein 
 Pre-Albumin 
 Transferrin 
          Among these reactants, Pre-Albumin, Transferrin were negative phase 
reactants, they tend to decrease during inflammatory reactions whereas others 
increase during any inflammatory and infective conditions.
20 
Inflammation and CVA 
The proposed mechanisms for role of inflammation in cerebrovascular disease 
are: 
   Soon after an ischemic stroke, acute atherothrombotic event brings out 
an ischemic necrosis in acute cerebral infarction and brain damage. 
 Formation of atheromatous plaques and fatty streaks (atherosclerosis) is 
a lifelong process. 
  In Intracerebral hemorrhage, brain injury is delayed. 
 Sub-Arachnoid hemorrhage causes vasospasm leading on to 
Cerebrovascular accidents. 
HIGHLY SENSITIVE C-REACTIVE PROTEIN 
         C-reactive protein (CRP) is considered as an hallmark of the acute-phase 
response and seems to be a blood marker of inflammation. hsCRP is now 
considered as a marker  of Atherosclerosis, and metabolic syndrome and helps 
to predicts cardiovascular events such as myocardial infarction, 
cerebrovascular accidents, peripheral arterial disease, sudden cardiac  death.
[21]
 
         In 1930, Tillet and Francis discovered C-reactive protein (CRP), as a 
substance in serum sample of the patient, which is secreted in response to 
acute inflammation that reacted with C-polysaccharide of pneumococcus in 
Rockfeller hospital. This fraction was named as ' C ' Substance. Lofstrom 
noted non specific capsular swelling when few pneumococcal strains were 
mixed with patient‟s sera and noted that CRP gets elevated in infective, non-
infective conditions, malignant neoplasms, cellular debris, tissue necrosis. 
Synthesis and metabolism 
  CRP is synthesized mainly in liver.  In both infectious, non-infectious 
conditions, the rate of synthesis and secretion of CRP are elevated under the 
influence of interleukins 1, interleukins 6, interleukins 17, Prostaglandins E, 
and Tumor necrosis Factor. The normal value of hsCRP is 3mg /L. Catabolism 
of CRP occurs in Liver, hence it was apparently removed from circulation and 
the plasma half life is 19 hours, inspite of disease status. So CRP levels in 
Blood mainly depend on the rate of production. In Inflammatory conditions, 
these values get increased and doubles in every 8 hours and peaks around 36-
50 hours. CRP concentration can may rises more than 500 mg/l which means, 
as much as a 1000-fold or more concentration change, in acute inflammatory 
states. The hsCRP is the lower concentration of normal CRP values, whereas 
the normal reference range of CRP is 0-8 mg/L. 
 
Structure 
CRP, belonging to pentraxin family, has a pentameric non-glycosylated 
polypeptide with covalent binding in between these proteins, arranged in 
cyclic pentameric symmetry, arranged in a disc like configuration with a 
central core. Human CRP has a molecular mass of 115,135 Da. 
Functions of CRP 
 Activator of Classical Complement Pathway and brings out endothelial 
dysfunction. 
 Promotes opsonisation and it stimulates the procoagulant state. 
 Decreases the release of platelets in acute inflammatory conditions. 
 Increases the activity and motility of phagocytic cells. 
Indications 
1. Inflammatory conditions 
 Rheumatoid Arthritis 
 Reiter‟s syndrome 
 Rheumatic fever 
 Ankylosing spondylosis 
2. Vascular causes  
 Bechet syndrome, 
 Polymyalgia rheumatic,  
 Polyarteritis  nodosa       
3. Infective conditions 
 Bacteial infections 
 Viral infections 
 Fungal infections 
 Sepsis  
 Pyogenic meningitis 
 Intercurrent infections in leukemia 
4. Screening test for different organic disease 
5. To assess the prognosis and to predict the functional outcome of  diseases in  
     acute myocardial infarction, cerebrovascular accident. 
6. In inflammatory conditions where CRP level is normal or not elevated are 
 SLE 
 Dermatomyositis 
 Ulcerative colitis 
HSCRP VALUES 
HSCRP VALUES 
(MG/DL) 
INFERENCE 
0-1 LOW RISK 
1-3 INTERMEDIATE RISK 
>3 HIGH RISK 
 
NATIONAL INSTITUTE OF HEALTH STROKE SCALE (NIHSS) 
Neurological Examination stroke scale which has 15 items was designed 
by Thomas Brott in the year 1989, to know the impact of Acute Cerebral 
Infarction on neurological outcome and recovery. Due to its pit falls, it was 
modified later, to frame NIHSS.
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NIHSS will have a total score of 42. Patients with completed stroke, 
hemiplegia, hemianopia, hemineglect, Aphasia, facial palsy will have 
maximum score of 31. 
1. Cranial Nerve/ Visual disturbances 
2. Level of Consciousness 
3. Motor weakness 
4. Language/ Neglect – were the four important areas to be taken into 
account. Even based on this clinical parameter, scores can be computed 
and severity can be assessed. 
Merits of NIHSS 
 Helps in diagnosing Cerebrovascular accidents. 
 To know the prognosis of stroke  
 To determine functional disability 
 Rapid way of assessing the patient, which can be done in 10 minutes. 
 Tested 
Item 
Title Response & Scores 
1A Level of 
Consciousness 
0 – Patient is very alert 
1 – Ready to fall asleep, lack of 
attention, patient will respond 
to painful stimuli 
2 – Patient is not alert or 
oriented to time, person, place 
and remains in a state of 
confusion or frank delirium 
3 – Patient is Comatosed and 
not responding to painful 
stimuli 
 
1B Orientation 
Questions 
0 – Here patient answers 
correctly to 2 simple 
questions 
1 – Patient will answer 1 
question correctly 
2 – Patient will not 
answer correctly to any 
question 
1C Response to 
Commands 
0 – Patient will do both 
work  and task s perfectly 
1 – Patient will do one 
task perfectly 
2 – Patient will not do 
both tasks 
2 Gaze 0 – Patient has normal 
horizontal movements 
1 – Patient can have gaze 
palsy which is partial 
2–Complete 
ophthalmoplegia 
3 Field of vision 0 – Patients visual field is 
normal 
1 – Patient will have 
Hemi-anopia which  is 
partial 
2 – Patient will have 
Hemi-anopia which is 
complete 
3 – Here Hemi-anopia is 
bilateral 
4 Facial 
Movements 
0 – Normal 
1 – Here facial palsy is 
subtle 
2 – Patient will have 
facial weakness which is 
incomplete 
3 – Here facial palsy is 
complete which is 
unilateral 
5 Motor  
Functions 
(Arm) 
a) Left 
b) Right 
0 – No fall when both 
forearms are stretched 
out and kept in supinated 
position 
1 – Fall of forearm and 
hand occurs before 5 
seconds 
2 – Forearm and hands 
fall & supinate before 10 
seconds 
3 – No movement against 
gravity 
4 – Total paralysis 
6 Motor 
Functions 
(Leg) 
a) Left 
b) Right 
0 – No drift 
1 – Drift of leg oocurs 
before 5 seconds 
2 – Fall of leg occurs 
even before 5 seconds 
3 – No movement against 
gravity 
4 – Total paralysis 
7 Limb Inco-
ordination 
0 – Normal 
1 – Inco-ordination of 
only one limb 
2 – Inco-ordination of 
two limbs 
8 Sensory 0 – Patient will not have 
any sensory loss 
1 – Here sensory loss is 
mild 
2 – Here patient will have 
severe sensory loss 
9 Language 0 – Patient can 
communicate and 
comprehend the language 
properly 
1 – Patient will have 
subtle loss of speech 
2 – Patient will have 
severe loss of  speech 
3 – Patient will have both 
Broca & Wernicke‟s 
aphasia or mute 
 
10 Articulation 0 – Normal 
1 – Articulation defect is 
mild 
2 – Articulation defect is 
severe 
11 Extinction or 
inattention 
0 – Absent 
1 – One modality of 
sensation is loss 
2 – Severe loss of 
sensation 
 
Interpretation of NIHSS Score 
0 – No stroke 
1-4 – Minor stroke 
5-15 – Moderate stroke 
16-20 – Moderate to severe stroke 
21-41 – Severe stroke 
Modified Rankin Scale (MRS) 
Dr. John Rankin designed Modified Rankin Scale in 1957, used to assess 
the clinical outcome and the neurological disability in stroke patients. 
Parameters:  MRS carries a total score of 0-6. 
Score Observations 
0 Patient should not have any symptoms at all 
1 Patient should not have any significant disability inspite of 
presence of symptoms and can able to perform routine daily 
normal activities 
2 Patient will have slight disability and the person cannot 
perform all routine activities but manages to do his personal 
work without help 
3 Patient is having moderate disability and needs some help, but 
able to walk without assistance 
4 Patient will have moderately severe disability and cannot walk 
without help and unable to do his personal affairs without 
assistance 
5 Here patient is having severe  disability and the affected 
individual is bedridden,  urinary incontinence will be present 
and needs continuous nursing care and attention 
6 Dead 
 
Studies supporting Stroke is an inflammatory process 
Yusuf Tamam et al.
25
, 2005 explain the role of acute phase proteins in 
acute stroke which is an inflammatory process. Here in this study, totally 53 
patients were taken and age controlled subjects were also taken. Six APP (such 
as Haptoglobin, ceruloplasmin, hsCRP, fibrinogen, C3 and C4) were done on 
day 1, 3, 5 & 10. hsCRP, C3 and C4 levels were raised significantly on day 3, 
complements C3 and C4 on 5
th
 day and Haptoglobin on 10
th
 day. All these 
findings suggest stroke is an inflammatory process. 
 
Studies supporting Stroke is an inflammatory process 
Study Year of study done 
Muir et al.
26
 1999 
Leiden 85 plus study 2002 
Eikelboom et al.
28 
2003 
Yusuf tamam et al.
25
 2005 
 
Prognostic significance of hsCRP in Acute Ischemic Stroke 
        In Muir et al.26228 cases of ischemic stroke were taken and was followed 
for a period of 950 days. Geometric mean CRP concentration was 10.1 mg / L. 
Mortality rate was more in patients with CRP > 10.1 mg/l than other group of 
patients with CRP ≤10.1 mg / L. These studies reveal that inflammation play a 
role in Acute Ischemic Stroke and also higher CRP predicts future 
Cardiovascular mortality. 
       In Bergen Stroke Study,
34
 CRP & NIHSS were measured in 498 patients 
with ischemic stroke within 24 hours of onset. NIHSS and CRP levels were 
seen while admitting the patient. CRP cut off of 3 mg/l was made. Recovery is 
measured using MRS & Barthel Index. Patients with high CRP along with 
high NIHSS (p=0.01) had long term mortality (p=0.0002). Patients with high 
CRP also had poor functional recovery and outcome. (MRS > 3, BI < 95) with 
p values as p =0.01 & p = 0.03. 
          John W Eikelboom et al., a case control study stroke cases  (202) were 
identified from 199 hospitals and blood samples were drawn for  CRP and 
patients with higher CRP values (8.50) correlate with stroke severity 
assessment by Oxford Handicap Scale score ( p=0.03 ) and Barthel index ( 
p=0.001 ). From these results the author concludes that there was an 
independent relationship between high CRP value and Ischemic stroke. 
         Relationship between hsCRP and clinical functional outcome after acute 
ischemic stroke in a Korean population was studied. In this study, hsCRP 
levels were taken within 24 hours and on 7
th
 day of onset in 417 Korean 
patients. MRS scanning was done after 12 months and hsCRP concentation got 
correlated significantly with MRS score. 
          In Hamidon et.al. 2004, Prognostic significance of CRP values in CVA 
patients were studied. For all ischemic stroke patients (about 84 patients) 
joined between May 2002 – July 2002 in Hospital University, Kebargsaan, 
Malaysia,   hsCRP was taken. After one month, Barthal Index was used to 
know the function disability. About 29 patients who had elevated CRP had 
severe functional disability and also patient had larger infarct. 
         In study conducted by Mario Di Napolis 2001, prognostic value of 
hsCRP in acute ischemic stroke was studied. Hundred and ninty three patients 
were chosen and hsCRP levels were taken on admission and at the time of 
discharge. From receiver operator curve, CRP cut off of 1.5 mg/l which 
provides optimum senstivity and specificity was made. Admission CRP 
(Hazard ratio 2.78 p= 0.0021) and discharge CRP (Hazard ratio 9.42, 
p<0.0001) was also obtained. This study reveals discharge CRP was 
considered as the strongest independent marker of future worse outcome (in 
terms of cardio vascular mortality). 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
SETTING: 
Patients admitted in medical ward, Government Rajaji Hospital, Madurai 
COLABORATIVE DEPARTMENTS: 
Department of Biochemistry, Neurology, Radiology, Medicine, Madurai 
Medical College, Madurai. 
STUDY DESIGN: 
Prospective cross sectional observation study 
PERIOD OF STUDY: 
March 2012 to October 2012 
STUDY POPULATION: 
50 Acute ischemic stroke patients admitted in medical ward, Government 
Rajaji Hospital, Madurai. 
DEFINITIONS FOLLOWED IN THIS STUDY: 
STROKE: 
 As per WHO criteria, Acute Stroke is defined as “rapidly developing 
focal or generalized (for coma patients) neurological alterations in cerebral 
function with signs and symptoms lasting for more than 24 hours or leading on 
to death, without any apparent cause for stroke except vascular etiology. 
HYPERTENSION: 
 Hypertension was defined as patients with previous record of atleast 2 
recordings of >140 / 90 mmHg or patients who are on regular intake of anti 
hypertensive medications. 
DIABETES: 
 Diabetes was defined as patients with Random Blood Sugar of 
>200mg/dL, Fasting blood sugar of >126 mg/dL, Post prandial blood sugar of 
>200mg/dL or patients who are in need of regular intake of anti-diabetic 
drugs. 
DYSLIPIDEMIA: 
 Dyslipidemia was defined as patients with Fasting Serum Cholesterol 
values of more than 220 mgs/dL. 
HSCRP: 
 Immunoturbidity method was adopted to find hsCRP values. HsCRP 
cut-off value of 3 mg /dL was made.These HsCRP values were correlated with 
NIHSS score at the admission and MODIFIED RANKIN SCALE score which 
denotes the functional recovery of the patient after 4 weeks. Patients with 
elevated HsCRP will have high NIHSS score which denotes the severity and 
high MRS score which denotes the poor outcome. 
NIHSS SCORE 
NIHSS scoring was made based on the clinical parameters. In this study, 
patients with a score of 1- 4 were considered as MILD, 5-15 were considered 
as MODERATE, >15 were considered as SEVERE category. 
INCLUSION CRITERIA: 
1. All patients with new onset focal neurological deficit following ischemic 
stroke, presented within 48 hours of onset of stroke are taken into study. 
2. Patients >14 years and of both sexes are included in the study. 
3. Patients with new onset stroke with past history of hypertension, diabetes 
mellitus, dyslipidemeia, smoking, alcohol were included. 
EXCLUSION CRITERIA: 
1. Patients with age more than 80 years were excluded. 
2. Patients with malignancy and clinical findings and blood investigations  
    suggestive of infection were excluded.   
3. Individuals with Connective Tissue disorders and Rheumatic heart disease, 
    Coronary Artery disease were excluded.  
4. Patients with prior history of transient ischemic attacks or reversible  
    ischemic neurological deficit, cerebrovascular accidents were excluded. 
     
5. Patients with features of haemorrhage such as sub-dural haemorrhage,  
     sub-arachnoid haemorrhage, and intracerebral haemorrhage were excluded  
     with the aid of CT scan. 
6. History of recent surgery and trauma. 
7. CNS tumors. 
ETHICAL CLEARANCE: 
Necessary ethical clearance was obtained from ethical committee, 
Government Rajai Hospital, Madurai. 
STUDY METHODS: 
50 patients who had acute ischemic stroke were taken for study. Those 
patients who got admitted within 48 hours of onset of stroke were only 
included in this study. As soon as patient got admitted, verbal consent was 
obtained from patient or attenders. Then complete and relevant medical 
history, complete neurological examination, routine blood and radiological 
investigations were done and all data were recorded in a standardized 
proforma. 
 CT scan was taken to exclude the haemorrhagic stroke and to identify 
the site or territory of infarct. Serum hsCRP level were taken as soon as patient 
got admitted in the hospital. National Institute of Health Stroke Scale (NIHSS) 
scoring was applied at the time of admission and these patients were 
categorized as mild, moderate and severe groups. 
This acute ischemic stroke patients were treated according to standard 
treatment protocols and in the study, and the patients were treated with 
Aspirin, Atorvastatin, physiotherapy and supportive care. None of the patients 
in the study group were thrombolysed. Anti edema measures were adopted 
with either intravenous Mannitol or oral Glycerol. Modified Rankin Scale was 
applied to know the functional recovery of the patient after 4 weeks when 
patient is on follow up and attending the review op. MRS score of 3,4,5,6 were 
included under Poor Outcome and scores of 1,2 were considered as Good 
outcome. 
STATISCAL METHODS 
 All the collected data were computed in Master chart. Statiscal data 
analysis was done. Chi Square test, Means, Standard deviation, „p‟ values 
were calculated. A „p‟ value less than 0.05 denotes significant relationship. 
Pearson‟s r correlation test and scatter plot analysis were also done for given 
data. 
 
 
RESULTS AND ANALYSIS 
  SEX DISTRIBUTION 
Total number of patients included in the study    = 50 (100%) 
Number of Male cases included in the study       = 29 (58%) 
Number of Female cases included in the study   = 21 (42%) 
TABLE 1 SEX DISTRIBUTION 
SEX NO.OF CASES PERCENTAGE 
MALE 29 58% 
FEMALE 21 42% 
TOTAL 50 100% 
 
 
 
SEX VS hsCRP 
     Out of 29 male patients , Number of male patients who had hsCRP  values 
< 3 mg/L are 14 ( 48.3 %) and the number of male patients who had hsCRP 
values ≥ 3 mg / L are 15 (51.7%).  
     And out of 21 female patients , 8 ( 38.1 % ) female cases had hsCRP values    
< 3 mg / L and 13 ( 61.9 % ) female patients had hsCRP level ≥ 3 mg/ L .   
TABLE 2     SEX VS hsCRP 
SEX NO.OF 
PATIENTS 
HsCR P (mg/L) TOTAL 
<3 ≥ 3 
MALE COUNT 14 15 29 
% 48.3% 51.7% 100.0% 
FEMALE COUNT 8 13 21 
% 38.1% 61.9% 100.0% 
TOTAL COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = 0 .474                  NOT SIGNIFICANT 
The correlation between sex and hsCRP was statistically not significant. 
 
 
AGE DISTRIBUTION 
Out of 50 patients, 11(22% ) patients were  in the age group of ≤ 50 
years and 39 ( 78% )patients were in the age group of  > 50 years. 
TABLE 3     AGE DISTRIBUTION 
 
AGE (IN YEARS) 
 
NO.OF PATIENTS 
 
≤ 50 
 
11 
 
> 50 
 
39 
 
TOTAL 
 
 
50 
 
 
 
 
AGE VS hsCRP 
Out of 11 (22%) patients who were in the age group of ≤ 50 years, 6 
(54.5% ) patients had hsCRP < 3 mg/L and 5 ( 45.5% )patients  had hsCRP ≥3 
mg/L. 
Out of 39 (78%) patients who were in the age group of   > 50 years, 16  
(41%) patients had hsCRP < 3 mg/L and 23 ( 59% ) patients  had hsCRP ≥3 
mg/L. 
TABLE 4    AGE VS hsCRP 
AGE (IN 
YEARS) 
NO. OF 
PATIENTS 
hsCRP ( mg/L)  
TOTAL <3 ≥3 
≤50 COUNT 6 5 11 
% 54.5% 45.5% 100.0% 
>50 COUNT 16 23 39 
% 41.0% 59.0% 100.0% 
Total COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = 0.503          NOT SIGNIFICANT 
The correlation of Age with hsCRP was statistically insignificant. 
 
 SMOKERS VS hsCRP  
              HsCRP profile was done in all 50 cases which includes both smokers 
and non smokers .Out of  28 patients  who are all non smokers , 12 (42.9% ) 
patients had hsCRP < 3 mg / L and 16 ( 57.1% ) patients had hsCRP ≥3 mg/L . 
Out of 22 patients, who are all smoking, 10 (45.5 % ) patients had 
hsCRP < 3 mg / L and 12 ( 54.5 % ) patients had hsCRP ≥3 mg/L . 
TABLE 6    SMOKERS VS hsCRP 
SMOKING NO.OF 
PATIENTS 
hsCRP( mg/L )  
TOTAL <3 ≥3 
NO COUNT 12 16 28 
% 42.9% 57.1% 100.0% 
YES COUNT 10 12 22 
% 45.5% 54.5% 100.0% 
TOTAL COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = 0 .854                NOT SIGNIFICANT 
The correlation between smokers and hsCRP was statiscally not significant. 
 
 ALCOHOLICS Vs hsCRP 
In both alcoholics and non alcoholics, hsCRP profile was done. The  
number of patients with hsCRP < 3 mg / L were 14 ( 48.3% )  and  hsCRP ≥3  
mg / L were 15 ( 51.7% ) among total 29 patients who were non alcoholics. 
The number of patients with hsCRP < 3 mg / L were 8 (38.1%)  and  
hsCRP ≥3  mg / L were 13 (61.9%) among total 21 patients who were 
alcoholics . 
TABLE 7 ALCOHOLICS Vs hsCRP 
ALCOHOL NO.OF 
PATIENTS 
hsCRP ( mg/ L) TOTAL 
<3 ≥3 
NO COUNT 14 15 29 
% 48.3% 51.7% 100.0% 
YES COUNT 8 13 21 
% 38.1% 61.9% 100.0% 
TOTAL COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = 0.474                NOT SIGNIFICANT 
The correlation between hsCRP and Alcoholics was statistically insignificant  
  
DIABETICS Vs hsCRP 
 hsCRP values were correlated with both diabetics and non diabetics 
patients. Among 11 non diabetics, 9 (81.8%) patients had hsCRP <3 mg / L 
and 2 (18.2%) patients had hsCRP ≥ 3 mg / L . 
 Among 39 diabetics, the number of patients with hsCRP <3 mg / L were 
13 (33.3%) and with hsCRP ≥ 3 mg / L were 26 (66.7%). 
TABLE 8  DIABETICS Vs hsCRP 
DIABETES NO.OF 
PATIENTS 
hsCRP( mg / L) TOTAL 
<3 ≥3 
NO COUNT 9 2 11 
% 81.8% 18.2% 100.0% 
YES COUNT 13 26 39 
% 33.3% 66.7% 100.0% 
TOTAL COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = 0 .006             SIGNIFICANT 
The correlation between hsCRP and Diabetes was significant statistically.  
 
 HYPERTENSION Vs hsCRP 
 hsCRP values were correlated in both hypertensives and non 
hypertensives patients. Out of 31 non hypertensive patients, 18 (58.1%) 
patients had hsCRP <3 mg / L and 13 (41.9%) patients had hsCRP ≥ 3 mg / L . 
 Out of 19 hypertensive patients, 4 (21.1%) patients had hsCRP <3 mg / 
L and 15 (78.9% ) patients had hsCRP ≥ 3 mg / L. 
TABLE 9   HYPERTENSION Vs hsCRP 
HTN NO.OF 
PATIENTS 
hsCRP (mg/L) TOTAL 
<3 ≥ 3 
NO COUNT 18 13 31 
% 58.1% 41.9% 100.0% 
YES COUNT 4 15 19 
% 21.1% 78.9% 100.0% 
TOTAL COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = .010                SIGNIFICANT 
The correlation between hsCRP and Hypertensives was statistically 
significant.  
 CHOLESTEROL vs hsCRP 
 hsCRP profile was seen in both dyslipidemic and non dyslipidemic 
patients . Among 12 non dyslipidemic patients, 11(91.7%) had hsCRP <3 mg / 
L and 1(8.3%) patients had hsCRP ≥ 3 mg / L. 
 Among 38 dyslipidemic patients, 11(28.9% ) had hsCRP <3 mg / L and 
27(71.1% ) patients had hsCRP ≥ 3 mg / L.  
TABLE 10   CHOLESTEROL vs hsCRP 
CHOLESETEROL NO.OF 
PATIENTS 
hsCRP(mg/L) TOTAL 
<3 ≥3 
NO COUNT 11 1 12 
% 91.7% 8.3% 100.0% 
YES COUNT 11 27 38 
% 28.9% 71.1% 100.0% 
TOTAL COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
P value = 0 .000              SIGNIFICANT 
The correlation between hsCRP and Dyslipidemic patients was statistically 
significant.  
 LOSS OF CONSCIOUSNESS Vs hsCRP 
In Patients with loss of consciousness, hsCRP profile was done. The 
number of patients with hsCRP < 3 mg /L were 21 (58.3% ) and hsCRP ≥ 3 
mg / L were 15  (41.7% ) among conscious patients. 
The number of patients with hsCRP < 3 mg /L were 1 (7.1%) and hsCRP 
≥ 3 mg / L were 13 (92.9%) among un-conscious patients. 
TABLE 11   LOSS OF CONSCIOUSNESS Vs hsCRP 
LOC NO.OF 
PATIENTS 
hsCRP(mg/L) TOTAL 
<3 ≥3 
NO COUNT 21 15 36 
% 58.3% 41.7% 100.0% 
YES COUNT 1 13 14 
% 7.1% 92.9% 100.0% 
TOTAL COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = 0 .001         SIGNIFICANT 
The correlation between hsCRP and Unconscious patients was statistically 
significant. 
 
INFARCT TERRITORY vs hsCRP 
 HsCRP profile was done in patients with various territory of infarct in ct 
brain. 
 Among ACA territory infarct patients, 7 (70.0%) patients had hsCRP < 3 
mg /L and 3 (30.0% ) had hsCRP ≥ 3 mg / L . 
 Among MCA territory infarct patients, 6 (20.7%) patients had hsCRP < 3 
mg /L and 23 (79.3%) had hsCRP ≥ 3 mg / L. 
 Among PCA territory infarct patients, 2 (100.0%) patients had hsCRP < 3 
mg /L and 0 patients had hsCRP ≥ 3 mg / L. 
Among others category which includes patients with watershed infarct and 
lacunar infarct in their CT films, 7(77.8%) patients had hsCRP mg / L > 3 
mg/L and 2 (22.2% ) had hsCRP ≥ 3 mg / L. 
TABLE 12   INFARCT TERRITORY vs hsCRP 
 
INFARCT TERRITORY 
NO OF 
PATIENTS 
hsCRP(mg/L)  
TOTAL <3 ≥3 
 
ACA 
COUNT 7 3 10 
% 70.0% 30.0% 100.0% 
 
MCA 
COUNT 6 23 29 
% 20.7% 79.3% 100.0% 
 
PCA 
COUNT 2 0 2 
% 100.0% 0.0% 100.0% 
OTHERS(WATERSHED 
INFARCT, LACUNAR 
COUNT 7 2 9 
% 77.8% 22.2% 100.0% 
INFARCT ) 
 
TOTAL 
COUNT 22 28 50 
% 44.0% 56.0% 100.0% 
p value = 0 .001                SIGNIFICANT 
The correlation between hsCRP and various territory of infarct in CT scan was 
statistically significant. 
 
DESCRIPTIVE STATISTICS 
The maximum and minimum mean values of hsCRP in the study are 6.9 
and 1.2 with an average mean of 3.544. 
The maximum and minimum mean values for NIHSS scoring system in 
the study is 33 and 5, with an average mean of 13.78 
The maximum and minimum mean values for MRS scoring system in 
the study is 6 and 1, with an average mean of 3.16.  
From this, it is evident that patients with a minimum hsCRP mean value 
of 1.2 had  
a) NIHSS score minimum mean value of 5 which comes under 
moderate group and  
b) MRS minimum mean value of 1 which comes under good 
outcome. 
And patients with hsCRP maximum mean value of 6.9 had 
a) NIHSS maximum mean value of 33 which comes under severe 
category 
b) MRS maximum mean value of 6 which comes under poor 
outcome. 
TABLE 13 DESCRIPTIVE STATISTICS 
 
VARIABLES 
 
No. 
 
MINIMUM 
 
MAXIMUM 
 
MEAN 
STD. 
DEVIATION 
HSCRP 50 1.2000 6.9000 3.544000 1.3635428 
NIHSS.SCORE 50 5 33 13.78 6.780 
MRS.SCORE 50 1 6 3.16 1.608 
 NIHSS DESCRIPTIVE STATISTICS 
Out of total 50 acute ischemic stroke cases, 30 (60%) patients comes 
under severity group of moderate under NIHSS scoring system.  
  And 20 (40%) patients comes under severity group of severe under 
NIHSS scoring system. 
 
 
 
TABLE 14 NIHSS DESCRIPTIVE STATISTICS 
 
NIHSS 
 
FREQUENCY 
 
PERCENT 
VALID 
PERCENT 
CUMULATIVE 
PERCENT 
MODERATE 30 60.0 60.0 60.0 
SEVERE 20 40.0 40.0 100.0 
TOTAL 50 100.0 100.0 00.0 
 
HSCRP VS NIHSS 
HsCRP profile was done in all patients and it was summated with 
various scoring categories of NIHSS. 
 Out of 30  cases who comes under moderate category in NIHSS , 22 ( 
73.33% )  cases had hsCRP values < 3mg / L and  8 ( 26.67 ) cases had hsCRP 
values ≥ 3 mg / L. 
 Out of 20 cases who were under severe category in NIHSS, no cases had 
hsCRP values < 3mg / L and 20 (100%) cases had hsCRP values ≥ 3 mg/L.  
TABLE 15   HSCRP VS NIHSS 
NIHSS NO.OF 
PATIENTS 
hsCRP(MG/L)  
TOTAL <3 ≥3 
 
MILD 
COUNT 0 0 0 
% 00.00 00 00 
 
MODERATE 
COUNT 22 8 30 
% 73.33 26.67 100 
 
SEVERE 
COUNT 0 20 20 
% 00.00 100 100 
 
TOTAL 
COUNT 22 28 50 
% 44 56 100 
 
 
 
PEARSON’S r CORRELATION AND SCATTER PLOT ANALYSIS 
This table denotes strong correlation between hsCRP and NIHSS score. 
Change in hsCRP values strongly correlates with change in NIHSS scores. 
There is also positive correlation between NIHSS score and HSCRP 
values, that is any increase in HSCRP will increase NIHSS scores and 
decrease in HSCRP values will decrease NIHSS scores. 
TABLE 16 HSCRP VS NIHSS 
 
hsCRP 
PEARSON 
CORRELATION 
1 .844 
P VALUE  .000 
N 50 50 
 
NIHSS 
PEARSON 
CORRELATION 
.844 1 
P VALUE .000  
N 50 50 
P =0.000              SIGNIFICANT 
The correlation between hsCRP and NIHSS was stastically significant. 
 
 
PEARSON’S r CORRELATION AND SCATTER PLOT ANALYSIS 
Scatterplot analysis reveals that there is a positive correlation between 
HSCRP values and NIHSS scores. Increase in HSCRP increases with NIHSS 
scores. 
 
PEARSON’S r CORRELATION AND SCATTER PLOT ANALYSIS 
BETWEEN hsCRP VALUES AND NIHSS SCORES 
 
 
MODIFIED RANKIN SCALE 
Among 50 total cases of stroke, 20 (40%) patients comes under good 
outcome by MRS scoring system and 30 (60%) patients comes under poor 
outcome by MRS scoring system. 
TABLE 17 MODIFIED RANKIN SCALE DESCRIPTIVE STATISTICS 
 
MRS 
 
FREQUENCY 
 
PERCENT 
VALID 
PERCENT 
CUMULATIVE 
PERCENT 
GOOD 20 40.0 40.0 40.0 
POOR 30 60.0 60.0 100.0 
TOTAL 50 100.0 100.0  
 
 
 
hsCRP VS MODIFIED RANKIN SCALE 
 hsCRP   values were correlated with various outcomes in Modified Rankin 
Scale. 
 Among 20 good outcome patients, 16 (80%) cases had hsCRP values < 
3mg / L and 4 ( 20% ) cases had hsCRP values ≥ 3 mg / L . 
 Among 30 poor outcome patients, 6 (20%) cases had hsCRP values < 3mg 
/ L and 24 (80%) cases had hsCRP values ≥ 3 mg / L. 
TABLE 18  hsCRP VS  MODIFIED RANKIN SCALE 
 
MRS 
NO.OF 
PATIENTS 
hsCRP(MG/L)  
TOTAL <3 ≥3 
 
GOOD 
COUNT 16 4 20 
% 80 20 100 
 
POOR 
COUNT 6 24 30 
% 20 80 100 
 
TOTAL 
COUNT 22 28 50 
% 44 56 100 
 
 
 
 
PEARSON’S  r CORRELATION AND SCATTER PLOT ANALYSIS 
This table denotes strong correlation between hsCRP and MRS score. 
Change in hsCRP values strongly correlates with change in MRS scores. 
There is also positive correlation between MRS score and hsCRP values, 
that is any increase in hsCRP will increase MRS scores and decrease in hsCRP 
values will decrease MRS scores. 
TABLE 19 hsCRP VS MODIFIED RANKIN SCALE 
  hsCRP(MG/L) MRS-SCORE 
 
hsCRP 
PEARSON 
CORRELATION 
1 .900 
P VALUE  .000 
N 50 50 
 
MRS SCORE 
PEARSON 
CORRELATION 
.900
**
 1 
P VALUE .000  
N 50 50 
p value = .000             SIGNIFICANT 
The correlation between hsCRP and MRS scale was statistically significant. 
 
PEARSON’S r CORRELATION AND SCATTER PLOT ANALYSIS 
Scatterplot analysis reveals that there is a positive correlation between 
hsCRP values and MRS scores .Increase in hsCRP increases with MRS scores. 
PEARSON’S r CORRELATION AND SCATTER PLOT ANALYSIS 
BETWEEN hsCRP VALUES AND MRS SCORES 
 
 
 
 
 
DISCUSSION 
Stroke is now considered as a major consequence of cerebrovascular 
accidents and health hazard to the society. In this study of prognostic 
significance of   hsCRP in Acute Ischemic Stroke consists of a group of 50 
patients who were admitted in Government Rajaji Hospital from March 2012 
to October 2012. In this study, hsCRP was taken within 48 hrs and NIHSS 
scoring was applied on the day of admission. Totally 50 cases were included in 
the study. Among the 50 cases included in this study 28 cases (56%) had 
hsCRP values ≥ 3 mg/l and 22 cases (44%) had hsCRP < 3 mg/l. 
Number of patients died in this group is 6. All these patients had a      
hsCRP of ≥ 3 mg/l. 
 Out of these 28 cases who has hsCRP  ≥ 3 mg/l, 26.67% of cases comes 
under moderately severe category and 73.33% cases comes under severe 
category. On the other hand, among the remaining 22 cases who had  hsCRP 
<3mg/l, all the 22 cases comes under moderately severe and none in severe 
group.  
 Pearson‟s r correlation also reveals the strong correlation between 
hsCRP and NIHSS scores. Pearson‟s r value is 0.844 which is close to one. A 
positive correlation exists between these 2 variables with a „p‟ value of 0.00, 
which is statistically significant.  
 Scatter plot analysis reveals the positive correlation between hsCRP & 
NIHSS. Any increase or decrease in hsCRP score analogous linearly with 
increase/decrease severity score of NIHSS. 
Out of 28 cases with hsCRP ≥3 mg/l 4 cases were in good outcome 
category and 24 cases in poor outcome category of MRS scores. 
In contrast among 22 cases with hsCRP < 3 mg/l, 16 cases were in good 
outcome and 6 cases were in poor outcome category in MRS Score. Pearson‟s 
r correlation analysis reveals strong as well as positive correlation between 
hsCRP and MRS. Pearson‟s r value is  0.900 which is close to 1 and  is 
positive variable. So any increase in hsCRP will favour the poor outcome of 
patients in terms of death and severe disability.  
Studies favoring Prognostic Significance of hsCRP in Acute Ischemic 
Stroke 
S.No Studies Year 
1.  Muir et al.26 1993 
2.  Bocola V, Papa F et al.32 2001 
3.  Di Napoli M et al.30 2001,2005, 
2009 
4.  Wirnbeck et al.29 2002 
5.  John W. Erkel boem et al.27 2003 
6.  Hamidon et al.31 2004 
7.  Alessandro terruzzi et al. 2008 
8.  Bergen Stroke Study34 2009 
9.  Rahman KM et al.33 2011 
10.  Arenillas et al.28 2012 
Sex 
In the present study, Incidence of stroke patient in male is 58% whereas 
in female patients it is 42%. This incidence data was supported by Thomas 
Kuruvill et al.
35
 in which males has higher incidence than female and in 
younger age group. No significant relationship exists between Sex and hsCRP  
in the present study, which was supported by Y.Tamam et al. 2005. 
Age 
 In the present study, incidence of stroke is more common among patient 
with the age group of more than 50 years. And also hsCRP values are elevated 
in this age group, but it is not statistically significant. This was supported by 
Juan F. Arenillas et al. 2003. 
Smoking    
 Smoking and Alcohol was not statistically significant. This result is 
against the findings of Dahovska et al.
36
The small sample value (only 50 cases 
considered) may be the reason for this contradiction.   
Studies which shows hsCRP is not statiscally significant in relation to 
hsCRP. 
 
S.No Study Year 
1 Juan F.Arenillas 2003 
2 Y.Tamam et al. 2005 
 
Diabetes  
 In this present study, there is significant correlation between hsCRP and 
diabetes with a p-value of 0.006. This was supported by number of studies. 
Studies in favor of rise in blood sugar increases hsCRP level 
S.No Study Year 
1 Guo et al. 2003 
2 Paul M. Ridker et al.
37
 2003 
3 Bergen Stroke Study 2009 
 
Hypertension 
In this present study, there is a significant correlation between hsCRP 
and Hypertension with a p value of 0.01. These findings are in agreement with 
following studies conducted by Xu T., Liu y.et al.
38
 in 2008 and Nadir Rifai et 
al. in 2005. 
Cholesterol 
In the present study, there is a significant correlation between hsCRP 
and Serum Cholesterol level with a p value of 0.00. This findings were similar 
and in concordance with Cesari et al.
39
 2003 and Ridker et al. in 200.
40
 
Infarct territory 
 In this present study, there is a significant correlation between infarct 
and hsCRP with a p value of 0.001. This reveals close association between 
Atherosclerosis and occurrence of newer ischemic events, which are caused by 
large occlusion of large intracranial vessels. This was supported by Arenillas 
et al. in 2003. 
 This study demonstrates the prognostic significance of hsCRP in acute 
ischemic stroke patients in correlation with stroke scores, which were 
measured at the time of admission (NIHSS) and four weeks after discharge 
(MRS). 
 This study also demonstrates the significant correlation between hsCRP 
and cordiovascular risk factors such as diabetes, hypertension, and cholesterol 
level. Stroke is common in this risk groups and had significantly higher 
hsCRP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 This present study is a cross sectional observation study of prognostic 
significance of highly sensitive C-reactive protein in acute ischemic 
stroke patients. 
 The present study shows male predominance with majority of patients in 
the age group of greater than 50 years. 
 The present study revealed significant association between hsCRP and 
Diabetes Mellitus, Hypertension & Cholesterol level. 
 This study demonstrates the significant rise in hsCRP in ischemic stroke 
patients in correlation with high scores with NIHSS which indicates the 
severity. 
 This study reveals the poor outcome in correlation with high hsCRP 
values and good outcome in correlation with low hsCRP values. 
 This study also explains statistically significant relationship between 
hsCRP and infarct. 
 There is no statistically significant relationship between hsCRP and age, 
sex, smoking and alcohol.     
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PROFORMA 
 
 NAME:                                        IP NO:                         SERIAL  NO:  
 
AGE:             
 
SEX:  
 
OCCUPATION:  
 
ADDRESS:  
 
DATE AND TIME OF STROKE:  
  
  
DATE OF ADMISSION : 
 
STROKE: RISK FACTORS  
                                                         SYSTEMIC HYPERTENSION    Y/N  
  
                                                                   DIABETES MELLITUS     Y/N  
                                                                                        
                                                                                        SMOKING      Y/N  
                                                                                      
                                                                                ALCOHOLISM      Y/N  
  
                                                                   HIGH CHOLESTEROL      Y/N  
  
                                                                                                  IHD       Y/N  
  
                                                                                                 RHD       Y/N  
  
                                                                                                   AF        Y/N  
  
 
  
 
PAST HISTORY OF STROKE :                                                         Y/N  
 
CLINICAL EXAMINATION:  
  
PULSE RATE:                       BP:  
 
CVS:  
 
RS:  
 
ABDOMEN:  
 
CNS: 
 
 ACUTE STROKE SYMPTOMS AND SIGNS  
  
SYMPTOMS  
  
         HEADACHE   
  
        GIDDINESS 
         
        LOSS OF CONSCIOUSNES   
  
        VOMITING   
  
        GAIT DISTURBANCE  
  
        CONVULSIONS  
  
         SPEECH DEFICIT   
  
SIGNS  
  
       SPEECH DEFICIT  
  
       HEMIANOPIA  
  
       DIPLOPIA  
  
       MOTOR SYSTEM  
  
                      PARESIS AT ANY SITE  
  
                      PARESIS OF ARMS                     Y/N                    R/L/B  
  
                      PARESI OF LEGS                         Y/N                    R/L/B  
  
                      PARESIS OF FACE                      Y/N                     R/L/B  
  
                       FIRST INVOLVED                      FACE / ARMS /  LEGS  
  
                       NO SUCH ORDER                       Y/N  
  
                SENSORY DEFICIT                             Y/N  
  
                CEREBELLAR SIGNS                         Y/N   
 
 
NIHSS SCORE AT THE TIME OF ADMISSION – MILD / MODERATE / 
SEVERE 
  
MRS AFTER 4 WEEKS :                                    00/01/02/03/04/05/06   
 
INVESTIGATIONS:  
 
HB%:  
 
TOTAL COUNT:  
 
DIFFERENTIAL COUNT     P-       , L-        , E-       , M-       , B-  
 
ESR:  
 
HS-CRP:  
  
BLOOD UREA:  
 
BLOOD SUGAR:  
 
SERUM CREATININE:  
 
SERUM ELECTROLYTES:  
 
SERUM CHOLESTEROL:  
  
ECG:  
 
CT BRAIN AND FINDING :  
  
HAEMORRHAGE               :     Y/N  
   
INFARCT                           :     Y/N  
  
LOCATION                        :    ACA/MCA/PCA 
                                                      
                                           WATER SHED/GLOBAL/LACUNAR/OTHERS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NAME 
A
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S
E
X
 
RISK FACTORS CLINICAL FEATURES 
TERRITORY OF 
INFARCT  
h
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O
/W
 
   
   
   
 M
IL
D
 
M
O
D
E
R
 
S
E
V
E
R
E
 
   
   
   
 P
O
O
R
 
G
O
O
D
 
AMASI 68 M Y Y N Y Y N F Y Y N - Y - - 3.8 - 14 - 4 - 
KANDAN 57 M N Y N Y N N F Y Y N - Y - - 2.9 - 10 - 3 - 
PERUMAL 70 M Y Y Y N Y Y F Y Y N - Y - - 6.8 - - 23 6 - 
KANIYAN 56 M Y Y N N N N F N N Y - - - L 2 - 7 - - 1 
JOTHI 68 F N N Y Y Y Y V Y N Y - Y - - 5 - - 22 5 - 
CHANDRA 61 F N N Y Y Y N F Y Y N Y - - - 3.4 - - 20 4 - 
HARIHARA
N 41 M Y Y N Y Y Y F Y N Y - Y - - 4.2 - - 25 5 - 
GURU 57 M N Y Y N Y N V Y Y N - - - L 2.9 - 13 - 3 - 
MANI 72 M Y Y N Y N N F Y Y N Y - - - 2.5 - 4 - - 2 
NAGARAJ 69 M Y Y Y Y Y N F Y N Y Y - - - 2 - 9 - - 1 
NALINI 68 F N N Y N N N N Y N Y - - - L 2.8 - 7 - - 1 
CHANDRA
N 76 M N Y Y Y Y Y V Y Y N - - - L 6.9 - - 26 6 - 
DEVARAJ 79 M Y N N N N N F Y N Y - Y - - 2.9 - 8 - - 2 
DURAI 60 M Y Y Y N Y Y F Y N Y - - Y - 2.8 - 14 - 3 - 
GUNALAN 58 M Y N N N N N N N N Y Y - - - 2.3 - 8 - - 1 
AMMANI 78 F N N Y N Y N F N N Y - Y - - 3.8 - 14 - 3 - 
GOWRI 50 F N N Y N Y Y F Y Y N - Y - - 4.4 - - 18 4 - 
ASHOK 36 M N Y Y Y Y N F N N Y - Y - - 5.1 - - 15 3 - 
ALAGU 60 M Y Y Y N N N F Y Y N - Y - W 3.2 - 7 - - 2 
BALAGUR
U 45 M N Y Y N Y N N N N Y - - - - 2.1 - 9 - - 2 
CHINNAIY
A 68 M Y N N N Y N F Y Y N Y - - - 2.7 - 10 - 3 - 
HARINI 56 F N N Y N Y N F Y Y N - Y - - 5.5 - - 16 5 - 
KANI 72 F N N Y N Y N F Y N Y - Y - - 4.2 - - 18 5 - 
PETHI 56 F N N Y Y Y Y F Y Y N - Y - - 6.4 - - 27 6 - 
AKILAN 43 M Y N N N N N N N N Y - - - L 2.5 - 6 - - 2 
KAMAL 28 M N N Y N Y N F Y Y N - Y - - 3.7 - - 18 4 - 
MOORTHY 56 M Y Y Y N Y Y F Y Y N - Y - - 6.4 - - 24 6 - 
AKILA 69 F N N Y N Y N F Y N Y Y - - L 3.2 - 8 - - 2 
SARASU 70 F N N Y N Y N F N N Y - - - - 2.5 - 13 - 3 - 
INDIRAN 46 M Y Y Y Y Y Y F Y Y N - Y - - 4.8 - - 19 5 - 
LALITHA 56 F N N Y N Y N F Y N Y - Y - - 3.5 - - 12 - 2 
MANI 63 M Y Y Y Y Y Y F 
 
Y N - Y - - 5.8 - - 24 6 - 
MARIAMM
AL 67 F N N N N N N F N N Y Y - - - 1.2 - 6 - - 1 
LOGESH 45 M Y N Y N Y N F Y N Y - Y - - 2.8 - 13 - 3 - 
NALLAMM
AL 71 F N N Y Y Y Y F Y Y N - Y - - 3.4 - - 16 3 - 
MALARVIZ
HI 35 F N N Y N Y N F Y N Y - Y - - 2.5 - 10 - - 2 
MARISWA 54 F N N N N N N N Y N Y - - - L 2 - 7 - - 1 
RI 
OCHAPPA
N 72 M N Y Y N N N F N Y N Y - - - 2.1 - 7 - - 1 
PARVATHI 68 F N N Y Y Y N N N Y N - Y - - 3.5 - 14 - 3 - 
NAGESWA
RI 50 F N N Y N Y N F Y N Y - Y - - 2.8 - 12 - - 2 
MUTHU 69 M Y Y Y Y Y Y F Y N Y - - - G 5.1 - - 25 6 - 
RAKKU 70 F N N Y N Y N F Y N Y - Y - - 3.4 - 14 - 3 - 
RAMYA 50 F N N Y N Y N N N N Y - - Y - 2.6 - 7 - - 2 
DEVADAS 78 M Y Y Y Y Y Y F Y Y N - Y - - 4 - - 16 4 - 
FAZIL 68 M Y Y Y Y Y N F Y N Y - Y - - 3.7 - - 15 4 - 
ISMAIL 58 M Y N Y N Y N F Y Y N - Y - - 3.9 - 14 - 3 - 
AIYSHA  69 F N N Y N Y N F N N Y Y - - - 3.1 - 5 - - 2 
SAMSATH 56 F N N Y Y Y N F Y Y N Y - - - 2 - 5 - - 1 
ELAVANIL 70 M Y N Y N N N F Y N Y - Y - - 2 - 7 
 
- 2 
GANESH 70 M Y Y Y Y Y Y F Y N Y - Y - - 4.1 - - 16 5 - 
 
Key words 
 
M- Male 
F- Female 
Y-Yes 
N- No 
LOC- Loss Of Conscious 
F-Facial Palsy (Column 10) 
V-Visual Disturbances 
Sp.Dis- Speech Disturbances 
L/G/W- Lacunar / Globular / Watershed infarct 
 
                          
 
 
 
 
ABBREVIATIONS 
1. ACA- Anterior Cerebral Artery 
2. AF- Atrial Fibrillation 
3. aPTT- Activated Partial Thromboplastin Time 
4. C3 AND C4- Complements C3 And C4 
5. CT- Computed Tomography 
6. CRP- C-Reactive Protein 
7. CVA-Cerebrovascular Accidents 
8. hsCRP- Highly Sensitive C-Reactive Protein 
9. HB- Haemoglobin 
10. IHD-Ischemic Heart Disease 
11. MCA-Middle Cerebral Artery 
12. MRI- Magnetic Resonance Imaging 
13. MRS-Modified Rankin Scale 
14. NIHSS-National Institute Of Health Stroke Scale 
15. PCA- Posterior Cerebral Artery 
16. RHD- Rheumatic Heart Disease 
17. rt-PA- Recombinant Tissue Plasminogen Activator 
18. UMN- Upper Motor Neuron 
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